Wang Peixiang, Zhao Liping, Jia Lihua, Wang Li
Int J Clin Pharmacol Ther. 2025 Jan;63(1):3-12. doi: 10.5414/CP204629.
To quantitatively and qualitatively evaluate research trends and hotspots for immune checkpoint inhibitors (ICIs), according to the most frequently cited clinical trials.
Numerous clinical trials have been carried out using ICIs for activating anti-tumor immunity in cancer patients. The most frequently cited clinical trials have been used as a database for achieving the objectives of this analysis.
The most frequently cited articles on ICIs meeting the inclusion criteria were extracted from the Web of Science database. Citation report information including annual outputs, most relevant journals, and country of origin together with burst references, keywords, information on co-occurrence, citation networks, and cluster topics were analyzed using standard bibliometric procedures.
A total of 112 most frequently cited articles on clinical trials of ICIs were retrieved for the period 2013 to 2021 of which the journal had the highest number of citations. Most studies originated in the U.S., and therefore studies from this country had a determinant effect of the results of the investigation. Burst reference topics included studies on ipilimumab for melanoma, anti-PD-L1 antibody in advanced cancer, anti-PD-1 antibody in cancer, nivolumab combined with ipilimumab or as monotherapy in untreated melanoma, and pembrolizumab for PD-L1 positive non-small-cell lung cancer. Nine clusters were grouped in the citation network. The topic/keywords "cancer", "immunotherapy", "PD-1 blockade", "PD-L1", "expression", "ipilimumab", "nivolumab", "pembrolizumab", and "safety" were the search priorities, whereas "multicenter", "resistance", "adverse events", and "renal-cell carcinoma" were seen as emerging topics in this specific field.
The bibliometric analysis of the most frequently cited clinical trials with ICIs provided information on the characteristics of the studies evaluated as well as hotpots and trends in evolving immunopharmacotherapy research on ICIs.
根据被引用频率最高的临床试验，对免疫检查点抑制剂（ICI）的研究趋势和热点进行定量和定性评估。
已经开展了大量使用ICI激活癌症患者抗肿瘤免疫的临床试验。被引用频率最高的临床试验被用作实现本分析目标的数据库。
从科学网数据库中提取符合纳入标准的关于ICI的被引用频率最高的文章。使用标准文献计量学程序分析包括年度产出、最相关期刊、原产国在内的引文报告信息，以及突发参考文献、关键词、共现信息、引文网络和聚类主题。
检索到2013年至2021年期间关于ICI临床试验的112篇被引用频率最高的文章，其中该期刊的被引用次数最多。大多数研究起源于美国，因此该国的研究对调查结果具有决定性影响。突发参考文献主题包括针对黑色素瘤的伊匹单抗研究、晚期癌症中的抗PD-L1抗体、癌症中的抗PD-1抗体、纳武单抗联合伊匹单抗或作为未治疗黑色素瘤的单药治疗，以及帕博利珠单抗用于PD-L1阳性非小细胞肺癌。在引文网络中分为九个聚类。主题/关键词“癌症”“免疫疗法”“PD-1阻断”“PD-L1”“表达”“伊匹单抗”“纳武单抗”“帕博利珠单抗”和“安全性”是搜索重点，而“多中心”“耐药性”“不良事件”和“肾细胞癌”被视为该特定领域的新兴主题。
对使用ICI的被引用频率最高的临床试验进行文献计量分析，提供了有关评估研究的特征以及ICI免疫药物治疗研究不断发展的热点和趋势的信息。
